Advanced Solid Tumors Clinical Trials in New Haven, Connecticut

12 studies are recruiting for advanced solid tumors in New Haven, Connecticut right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale Cancer Center, New Haven, Connecticut

   Locations

   9 in total

   Run by

   Revolution Medicines, Inc.

   See if you can join NCT07349537 on ClinicalTrials.gov

2. A Study of BG-C477 in Participants With Advanced Solid Tumors

   The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-C477 alone and in combination with anticancer agents in participants with selected advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale University Yale Cancer Center, New Haven, Connecticut

   Locations

   59 in total

   Run by

   BeOne Medicines

   See if you can join NCT06596473 on ClinicalTrials.gov

3. First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

   The goal of this clinical trial is to learn if the drug TUB-030 works to treat solid cancer in adults. The study will also explore the safety of TUB-030. The main questions it aims to answer are: To determine the safety and tolerability of TUB-030 To determine the maximum tolerated dose of TUB-030 …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale Cancer Center, New Haven, Connecticut

   Locations

   20 in total

   Run by

   Tubulis GmbH

   See if you can join NCT06657222 on ClinicalTrials.gov

4. Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

   The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expression, including non-small cell lung cancer (NSCLC), triple…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale University - Yale University School of Medicine, New Haven, Connecticut

   Locations

   9 in total

   Run by

   EMD Serono Research & Development Institute, Inc.

   See if you can join NCT07360314 on ClinicalTrials.gov

5. Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors

   The purpose of this trial is to learn about the safety and effectiveness of the antibody GEN1079 in participants with certain types of cancer. The trial has multiple parts. The first part of the trial tests different doses of GEN1079 to find out if it is safe and determine what are the best doses t…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale University, New Haven, Connecticut

   Locations

   12 in total

   Run by

   Genmab

   See if you can join NCT07387068 on ClinicalTrials.gov

6. A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

   The main goals of this clinical trial are to find out what the best dose of the study drug, OTP-01, is for patients with solid tumors through understanding how it is tolerated and any side effects that it may cause. The trial will also see if OTP-01 causes tumors to shrink and how the body processe…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale Cancer Center, New Haven, Connecticut

   Locations

   14 in total

   Run by

   Ottimo Pharma Limited

   See if you can join NCT07266428 on ClinicalTrials.gov

7. A Study of PHST001 in Advanced Solid Tumors

   This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b) in adult participants with advanced rela…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale Cancer Center, New Haven, Connecticut

   Locations

   20 in total

   Run by

   Pheast Therapeutics

   See if you can join NCT06840886 on ClinicalTrials.gov

8. A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.

   This is a Phase 1 study of SBO-154 in patients with advanced cancers who are unable to tolerate or have not previously responded to standard therapy available in the country. The study involves multiple doses and takes place at several centers.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale University - Yale Cancer Center, New Haven, Connecticut

   Locations

   16 in total

   Run by

   Sun Pharma Advanced Research Company Limited

   See if you can join NCT07042100 on ClinicalTrials.gov

9. A Study of ASP1002 in Adults for Treatment of Solid Tumors

   ASP1002 is being studied in people with tumors that have spread to nearby tissue (locally advanced) that cannot be removed by surgery (unresectable) or tumors that have spread to other parts of the body (metastatic). Claudin 4 protein, or CLDN4, is a protein found on tumors in different parts of th…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Yale University Cancer Center, New Haven, Connecticut

   Locations

   15 in total

   Run by

   Astellas Pharma Global Development, Inc.

   See if you can join NCT05719558 on ClinicalTrials.gov

10. Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

    Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Yale University, Yale Cancer Center, New Haven, Connecticut

    Locations

    15 in total

    Run by

    Ensem Therapeutics

    See if you can join NCT06993844 on ClinicalTrials.gov

11. Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

    This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Smilow Cancer Hospital (Yale University), New Haven, Connecticut

    Locations

    17 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT06040541 on ClinicalTrials.gov

12. A Clinical Study of YL205 in Patients With Advanced Solid Tumors

    This study is a multicenter, open-label, phase I/II study of YL205 in China to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of YL205 in the following selected patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Yale Cancer Center, New Haven, Connecticut

    Locations

    43 in total

    Run by

    MediLink Therapeutics (Suzhou) Co., Ltd.

    See if you can join NCT06459973 on ClinicalTrials.gov